Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 4311-4318

  Kim, Min Jung ^a   Yoo, Joo Yeon ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARGININE; BETA INTERFERON; INTERFERON STIMULATED GENE FACTOR 15; LYSINE; NONSTRUCTURAL PROTEIN 5A; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CYTOKINE; G1P2 PROTEIN, MOUSE; INTERFERON; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; UBIQUITIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CONTROLLED STUDY; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; REPLICON; VIRUS REPLICATION; ANIMAL; CELL STRAIN COS1; CERCOPITHECUS; IMMUNOBLOTTING; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; MOUSE; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOKINES; HEPACIVIRUS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTERFERON TYPE I; MICE; POLYMERASE CHAIN REACTION; UBIQUITINS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77958142546     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000098     Document Type: Article

References (50)

1. Lindenbach, B. D., and C. M. Rice. 2005. Unravelling hepatitis C virus replication from genome to function. Nature 436:933-938.
2. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
3. Clarke, B. 1997. Molecular virology of hepatitis C virus. J. Gen. Virol. 78:2397-2410.
4. Hijikata, M., N. Kato, Y. Ootsuyama, M. Nakagawa, and K. Shimotohno. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. USA 88:5547-5551.
5. Gale, M., Jr., B. Kwieciszewski, M. Dossett, H. Nakao, and M. G. Katze. 1999. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J. Virol. 73:6506-6516.
6. Ghosh, A. K., M. Majumder, R. Steele, P. Yaciuk, J. Chrivia, R. Ray, and R. B. Ray. 2000. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J. Biol. Chem. 275:7184-7188.
7. Lan, K. H., M. L. Sheu, S. J. Hwang, S. H. Yen, S. Y. Chen, J. C. Wu, Y. J. Wang, N. Kato, M. Omata, F. Y. Chang, and S. D. Lee. 2002. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 21:4801-4811.
8. Brass, V., E. Bieck, R. Montserret, B. Wölk, J. A. Hellings, H. E. Blum, F. Penin, and D. Moradpour. 2002. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 277:8130-8139.
9. Lundin, M., H. Lindström, C. Grönwall, and M. A. Persson. 2006. Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. J. Gen. Virol. 87:3263-3272.
10. Miyanari, Y., K. Atsuzawa, N. Usuda, K. Watashi, T. Hishiki, M. Zayas, R. Bartenschlager, T. Wakita, M. Hijikata, and K. Shimotohno. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9:1089-1097.
11. Di Bisceglie, A. M. 1998. Hepatitis C. Lancet 351:351-355.
12. De Francesco, R., and G. Migliaccio. 2005. Challenges and successes in developing new therapies for hepatitis C. Nature 436:953-960.
13. Feld, J. J., and J. H. Hoofnagle. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972.
14. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, and C. Sato. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:77-81.
15. Forestier, N., H. W. Reesink, C. J. Weegink, L. McNair, T. L. Kieffer, H. M. Chu, S. Purdy, P. L. Jansen, and S. Zeuzem. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640-648.
16. Modi, A. A., and J. H. Hoofnagle. 2007. New therapies for hepatitis C. Hepatology 46:615-617.
17. Sarrazin, C., R. Rouzier, F. Wagner, N. Forestier, D. Larrey, S. K. Gupta, M. Hussain, A. Shah, D. Cutler, J. Zhang, and S. Zeuzem. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132:1270-1278.
18. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124:783-801.
19. Hornung, V., J. Ellegast, S. Kim, K. Brzózka, A. Jung, H. Kato, H. Poeck, S. Akira, K. K. Conzelmann, M. Schlee, et al. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314:994-997.
20. Pichlmair, A., O. Schulz, C. P. Tan, T. I. Näslund, P. Liljeström, F. Weber, and C. Reis e Sousa. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314:997-1001.
21. Schröder, M., and A. G. Bowie. 2005. TLR3 in antiviral immunity: key player or bystander? Trends Immunol. 26:462-468.
22. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737.
23. Kawai, T., and S. Akira. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131-137.
24. Sen, G. C. 2001. Viruses and interferons. Annu. Rev. Microbiol. 55:255-281.
25. Smith, M. W., Z. N. Yue, M. J. Korth, H. A. Do, L. Boix, N. Fausto, J. Bruix, R. L. Carithers, Jr., and M. G. Katze. 2003. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 38:1458-1467.
26. Kim, K. I., N. V. Giannakopoulos, H. W. Virgin, and D. E. Zhang. 2004. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol. Cell. Biol. 24:9592-9600.
27. Kim, K. I., M. Yan, O. Malakhova, J. K. Luo, M. F. Shen, W. Zou, J. C. de la Torre, and D. E. Zhang. 2006. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol. Cell. Biol. 26:472-479.
28. Loeb, K. R., and A. L. Haas. 1992. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 267:7806-7813.
29. Lenschow, D. J., C. Lai, N. Frias-Staheli, N. V. Giannakopoulos, A. Lutz, T. Wolff, A. Osiak, B. Levine, R. E. Schmidt, A. Garcia-Sastre, et al. 2007. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. USA. 104:1371-1376.
30. Lenschow, D. J., N. V. Giannakopoulos, L. J. Gunn, C. Johnston, A. K. O'Guin, R. E. Schmidt, B. Levine, and H. W. Virgin, IV. 2005. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J. Virol. 79:13974-13983.
31. Yuan, W., and R. M. Krug. 2001. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 20:362-371.
32. Kim, M. J., S. Y. Hwang, T. Imaizumi, and J. Y. Yoo. 2008. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J. Virol. 82:1474-1483.
33. Okumura, A., G. Lu, I. Pitha-Rowe, and P. M. Pitha. 2006. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. USA 103:1440-1445.
34. Vrolijk, J. M., A. Kaul, B. E. Hansen, V. Lohmann, B. L. Haagmans, S. W. Schalm, and R. Bartenschlager. 2003. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110:201-209.
35. Hughes, M., S. Gretton, H. Shelton, D. D. Brown, C. J. McCormick, A. G. Angus, A. H. Patel, S. Griffin, and M. Harris. 2009. A conserved proline between domains II and III of hepatitis C virus NS5A influences both RNA replication and virus assembly. J. Virol. 83:10788-10796.
36. Lohmann, V., F. Körner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
37. Moradpour, D., M. J. Evans, R. Gosert, Z. Yuan, H. E. Blum, S. P. Goff, B. D. Lindenbach, and C. M. Rice. 2004. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 78:7400-7409.
38. Sauter, D., K. Himmelsbach, M. Kriegs, M. Carvajal Yepes, and E. Hildt. 2009. Localization determines function: N-terminally truncated NS5A fragments accumulate in the nucleus and impair HCV replication. J. Hepatol. 50:861-871.
39. Hou, W., Q. Tian, J. Zheng, and H. L. Bonkovsky. 2010. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology 138:1909-1919.
40. Okumura, A., P. M. Pitha, and R. N. Harty. 2008. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. Natl. Acad. Sci. USA 105:3974-3979.
41. Osiak, A., O. Utermöhlen, S. Niendorf, I. Horak, and K. P. Knobeloch. 2005. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol. Cell. Biol. 25:6338-6345.
42. Randall, G., L. Chen, M. Panis, A. K. Fischer, B. D. Lindenbach, J. Sun, J. Heathcote, C. M. Rice, A. M. Edwards, and I. D. McGilvray. 2006. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131:1584-1591.
43. Liu, M., X. L. Li, and B. A. Hassel. 2003. Proteasomes modulate conjugation to the ubiquitin-like protein, ISG15. J. Biol. Chem. 278:1594-1602.
44. Arimoto, K., H. Konishi, and K. Shimotohno. 2008. UbcH8 regulates ubiquitin and ISG15 conjugation to RIG-I. Mol. Immunol. 45:1078-1084.
45. Liu, Y. C., J. Penninger, and M. Karin. 2005. Immunity by ubiquitylation: a reversible process of modification. Nat. Rev. Immunol. 5:941-952.
46. Macdonald, A., and M. Harris. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85:2485-2502.
47. Chen, L., J. Sun, L. Meng, J. Heathcote, A. Edwards, and I. McGilvray. 2010. ISG15, a ubiquitin-like interferon stimulated gene, promotes Hepatitis C Virus production in vitro: Implications for chronic infection and response to treatment. J. Gen. Virol. 91:382-388.
48. McHutchison, J. G., E. J. Lawitz, M. L. Shiffman, A. J. Muir, G. W. Galler, J. McCone, L. M. Nyberg, W. M. Lee, R. H. Ghalib, E. R. Schiff, et al; IDEAL Study Team. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580-593.
49. Watanabe, S., N. Enomoto, K. Koike, N. Izumi, H. Takikawa, E. Hashimoto, F. Moriyasu, H. Kumada, and M. Imawari. 2010. Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol. Res. 40:135-144.
50. Stiffler, J. D., M. Nguyen, J. A. Sohn, C. Liu, D. Kaplan, and C. Seeger. 2009. Focal distribution of hepatitis C virus RNA in infected livers. PLoS ONE 4: e6661.